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RESUMO – A morfeia é uma doença inflamatória, rara, de etiologia desconhecida. Apresentamos o caso de uma mulher de 
35 anos com áreas de espessamento cutâneo no tronco e membros, e artralgias inflamatórias, com 18 meses de evolução. Os 
sintomas começaram 2 semanas após um tratamento de fertilidade. O exame físico e exames complementares confirmaram o 
diagnóstico de morfeia, pelo que iniciou deflazacorte e metotrexato com melhoria significativa dos sintomas.  Seis anos depois, a 
doente realizou um novo tratamento de fertilidade com agravamento da doença. A associação temporal entre os tratamentos de 
fertilidade e o início e agravamento da morfeia sugerem uma influência das hormonas sexuais na sua fisiopatologia.
PALAVRAS-CHAVE – Esclerodermia Localizada/etiologia; Esclerodermia Localizada/tratamento por fármacos; Hormonas/uso 
terapêutica; Infertilidade/tratamento.
Morphea and Hormonal Therapy: A Possible 
Association  
ABSTRACT – Morphea is a rare inflammatory disorder with an unknown etiology. We report the case of a 35-years-old woman 
presenting with an 18-month history of skin thickening on the extremities and trunk, and inflammatory arthralgia. Complaints star-
ted 2-weeks after a fertility treatment. The physical exam and workup confirmed the diagnosis of morphea, and the patient started 
treatment with deflazacort and methotrexate, with significant improvement. Six years later, the patient was submitted to another 
fertility treatment with exacerbation of the disease. The temporal association between the fertility treatments and the onset and 
further worsening of morphea suggest an influence of sex hormones on its pathophysiology. 
KEYWORDS – Hormones/adverse effects; Hormones/therapeutic use; Infertility/therapy; Scleroderma, Localized/etiology; Sclero-
derma, Localized/drug therapy.
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INTRODUCTION
Morphea, also known as localized scleroderma, is a 
rare inflammatory disorder, which ultimately leads to skin 
sclerosis. Its etiology is not well understood, but genetics 
and environmental factors appear to contribute. Three 
major mechanisms are thought to involve sclerosis: vascu-
lar disruption, activated T cells and altered connective tis-
sue production by fibroblasts.1-3 Triggering events include 
mechanical trauma, injections, vaccinations and X-irradia-
tion.1 Except for linear morphea, the disease as a higher 
prevalence among women favoring a potential role of sex 
hormones as a triggering agent for this disease.4 There 
are also reports of developing or worsening of morphea 
during pregnancy.5,6   
Skin involvement is characterized by an early inflamma-
tory and edematous stage, followed by sclerosis and sub-
sequent atrophy. The disease activity usually stops after 3 
to 6 years. In patients with deeper forms of morphea, con-
tractures may develop. Despite being limited to the skin, 
in severe and deep forms, extra-cutaneous manifestations 
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may occur and result in cosmetic mutilation and disability 
that persist after the resolution of disease activity.7,8
CASE REPORT 
A 35-years-old woman, smoker, was admitted at the 
rheumatology department due to an 18-month history 
of several areas of skin thickening. She also had inflam-
matory arthralgia, morning stiffness around 2 hours and 
significant functional impairment, without any other sys-
temic symptoms. These complaints started 2-weeks after 
a successful fertility treatment with an initial combina-
tion of follitropin beta and ganirelix (a GnRH antagonist), 
followed by human menopausal gonadotrophin, and 4 
months later with a combination of human menopausal 
gonadotrophin and cetrotide. During pregnancy lesions 
slowly developed, and the complaints worsened after deli-
very. The patient denied other relevant exposure or family 
history of autoimmune diseases. 
On physical examination, the patient had several large 
sclerotic hyperpigmented plaques on the extremities and 
trunk. Some lesions were associated with cutaneous atro-
phy and hypoesthesia (Figs. 1 a, b). There was left-hand 
flexor tenosynovitis, peripheral polyarthritis – involving 
right elbow and wrist; proximal interphalangeal (2nd to 5th 
on the right hand, and 2nd, 3rd and 5th on the left hand); 
and limited flexion of the left ankle joint due to skin thi-
ckening. There were no other relevant findings on physical 
examination. 
The laboratory workup, which included a complete 
blood cell count, erythrocyte sedimentation rate, C-reac-
tive protein (CRP), liver enzymes, creatinine, fasting glu-
cose, and autoimmunity panel, showed CRP of 1.0 mg/
dL (normal range <0.5 mg/dL), positive antinuclear an-
tibodies (ANA) 1/160 and negative extractable nuclear 
antigens (ENA), without any further alterations. Nail fold 
capillaroscopy was normal. Skin biopsy was not perfor-
med.
Based on the clinical picture the diagnosis of morphea 
was assumed and treatment was started with deflazacort 
6 mg/day (50 kg), methotrexate 15 mg/week (increased 
to 20 mg/week, and then switched to 15mg/week subcu-
taneous for gastrointestinal intolerance) and painkillers.
There was a significant improvement of pain and re-
mitting of polyarthritis and flexor tenosynovitis, after more 
than 6 months of immunosuppressive treatment. In the 
subsequent year the methotrexate dose was progressively 
reduced and deflazacort was withdrawn. Skin lesions re-
mained stable in size along the years, but skin sclerosis 
decreased progressively. 
Six years later, the patient was submitted to another 
fertility treatment (human menopausal gonadotrophin and 
a GnRH antagonist), that was not successful, but induced 
exacerbation of the disease within 1-month, characterized 
by worsening of previous lesions and two new scleroder-
matous lesions on the breasts, sparing the nipple (Fig. 1c). 
Treatment was again started with deflazacort 6 mg/day 
and oral methotrexate 10 mg/week, with good response.
DISCUSSION
Morphea affects both children and adults.7 Pregnan-
cy or other hormonal changes, like hormonal treatments, 
seem to predispose to this cutaneous disorder.5,6,9,10,12 The 
responsible mechanism for hormonal-related morphea 
is unknown, but hormonal and immunological changes 
could contribute to this disorder.10,11 Some clinical studies 
have shown, in menopausal women, the link between 
estrogen supplementation and skin thickening.10,11 Fur-
thermore, five cases of morphea that either developed 
or worsened during pregnancy were previously reported. 
In the reported cases, the proposed mechanism was mi-
chrochimerism, a process where cells transferred from the 
fetus to the mother, promote the activation of immune sys-
tem.5,6,9,12,13 
In this case, morphea started just after the first suc-
cessful fertility treatment and lesions worsened and new 
lesions developed after a second fertility treatment. Howe-
ver, to our knowledge, there are no published cases of 
morphea induced by drugs used for fertility treatments and 
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Figura 1 - (A, B) – Sclerodermatous lesions (linear and generalized) with cutaneous atrophy on the thigh and the abdominal left flank after first fertility 
treatment; (C) – Sclerodermatous lesions on the breasts that appeared only after second fertility treatment.
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it is not a reported side effect of these drugs. Nevertheless, 
it is known that progesterone raises 17 b-estradiol levels, 
which, through its skin receptors, regulate fibroblast pro-
liferation and tissue-degrading matrix metalloproteina-
se synthesis. Soldano et al demonstrated that estrogens 
stimulate the production of basic fibroblast growth fac-
tor and increase the secretion of the transforming growth 
factor (TGF-beta 1) in vitro. We hypothesized that higher 
levels of 17 b-estradiol induced by fertility treatment may 
be involved in promoting the cutaneous fibrotic process, 
as observed in this patient, but more studies need to be 
done.10,11 
Regarding treatment several retrospective studies re-
ported the use of methotrexate in morphea and its effica-
cy and safety have been reported in randomized control 
trials when used along with systemic steroids. Its antifi-
brotic effects was exerted via inhibition of inflammatory 
cytokines such as IL-2, IL-4, IL-6, IL-8, and TNF-alpha and 
adhesion molecules such as ICAM-1.14,15
The temporal association between the fertility treat-
ments and the onset and further worsening of morphea 
reinforces its relationship. This case highlights the possible 
influence of sex hormones on the pathophysiology of mor-
phea and the need to consider fertility drugs as a potential 
trigger to this disabling disease.
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